This article is more than 5 years old. Information may no longer be current.
Visx hyperopic wavefront LASIK treatment promising at 3 months
Click Here to Manage Email Alerts
OTTAWA — Three month results with the Visx WavePrint system for hyperopic LASIK show that the treatment is safe and accurate, according to an investigator here.
According to W. Bruce Jackson, MD, who reported results of a small prospective, nonrandomized clinical trial, the hyperopic corrections appear to be stable out to 3 months in patients with up to 3 D of hyperopia and 1.5 D of astigmatism. The mean spherical equivalent was 2.06 D.
The study included 7 patients treated bilaterally for hyperopia with a 9-mm blended optical zone.
At 1 month, 36% of eyes achieved an uncorrected visual acuity of 20/16 or better and 93% achieved UCVA of 20/20 or better.
The mean spherical equivalent at 1 month was plano, with 0.07 D of sphere.
At 3 months, 36% or eyes achieved 20/16 UCVA and 86% achieved 20/20 or better UCVA. All patients had 20/25 UCVA or better at 3 months.
Mean spherical equivalent did not change from 1 week to 1 month, but there was a 0.02 D mean change from 1 month to 3 months. Ninety-three percent of eyes were within ±0.5 D at 3 months.
At 1 month, 58% of eyes achieved a best corrected visual acuity of 20/16 or better and all eyes achieved BCVA of 20/20 or better.
At 3 months, 64% of eyes achieved BCVA of 20/16 or better and all eyes retained BCVA of 20/20 or better.
A tightening in point spread function was also seen. Regarding higher order aberrations, a reduction in root mean square from 0.49 to 0.24 was seen, which reflected the change in BCVA.
Dr. Jackson notes that future studies of the hyperopic wavefront guided system will include more patients as well as expanded treatment ranges.
More on the study will appear in the Dec. 1 issue of Ocular Surgery News.